首页> 外文期刊>生物医学研究杂志(英文版) >The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation
【24h】

The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation

机译:基因工程猪在为器官和细胞提供替代来源方面的潜力

获取原文
获取原文并翻译 | 示例
       

摘要

There is a critical shortage of organs, cells, and corneas from deceased human donors worldwide. There are also shortages of human blood for transfusion. A potential solution to all of these problems is the transplantation of organs, cells, and corneas from a readily available animal species, such as the pig, and the transfusion of red blood cells from pigs into humans. However, to achieve these ends, major immunologic and other barriers have to be overcome. Considerable progress has been made in this respect by the genetic modification of pigs to protect their tissues from the primate immune response and to correct several molecular incompatibilities that exist between pig and primate. These have included knockout of genes responsible for the expression of major antigenic targets for primate natural anti-pig antibodies, insertion of human complementand coagulation-regulatory transgenes, and knockdown of swine leukocyte antigens that stimulate the primate's adaptive immune response. As a result of these manipulations, the administration of novel immunosuppressive agents, and other innovations, pig hearts have now functioned in baboons for 6-8 months, pig islets have maintained normoglycemia in diabetic monkeys for > 1 year, and pig corneas have maintained transparency for several months. Clinical trials of pig islet transplantation are already in progress. Future developments will involve further genetic manipulations of the organsource pig, with most of the genes that are likely to be beneficial already identified.

著录项

  • 来源
    《生物医学研究杂志(英文版)》 |2013年第4期|249-253|共5页
  • 作者单位

    Thomas E.Starzl Transplantation Institute,University of Pittsburgh Medical Center,Pittsburgh,PA 15261,USA;

    Thomas E.Starzl Transplantation Institute,University of Pittsburgh Medical Center,Pittsburgh,PA 15261,USA;

    Thomas E.Starzl Transplantation Institute,University of Pittsburgh Medical Center,Pittsburgh,PA 15261,USA;

    Division of Immunogenetics,Children's Hospital of Pittsburgh,University of Pittsburgh,Pittsburgh,PA 15261,USA;

    Division of Immunogenetics,Children's Hospital of Pittsburgh,University of Pittsburgh,Pittsburgh,PA 15261,USA;

    Revivicor,Inc,Blacksburg,VA 24060,USA;

    Revivicor,Inc,Blacksburg,VA 24060,USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:48:00
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号